Abstract
Anti-nuclear antibodies (ANA) are fundamental for the diagnosis of autoimmune diseases, and have been determined by indirect immunofluorescence assay (IIFA) for decades. As the demand for ANA testing increased, alternative techniques were developed challenging the classic IIFA. These alternative platforms differ in their antigen profiles, sensitivity and specificity, raising uncertainties regarding standardisation and interpretation of incongruent results. Therefore, an international group of experts has created recommendations for ANA testing by different methods. Two groups of experts participated in this initiative. The European autoimmunity standardization initiative representing 15 European countries and the International Union of Immunologic Societies/World Health Organization/Arthritis Foundation/Centers for Disease Control and Prevention autoantibody standardising committee. A three-step process followed by a Delphi exercise with closed voting was applied. Twenty-five recommendations for determining ANA (1-13), anti-double stranded DNA antibodies (14-18), specific antibodies (19-23) and validation of methods (24-25) were created. Significant differences between experts were observed regarding recommendations 24-25 ( p
| Original language | English |
|---|---|
| Pages (from-to) | 17-23 |
| Number of pages | 7 |
| Journal | Annals of the Rheumatic Diseases |
| Volume | 73 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Jan 2014 |
Fingerprint
ASJC Scopus subject areas
- Rheumatology
- Immunology
- Biochemistry, Genetics and Molecular Biology(all)
- Immunology and Allergy
Cite this
International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. / Agmon-Levin, Nancy; Damoiseaux, Jan; Kallenberg, Cees; Sack, Ulrich; Witte, Torsten; Herold, Manfred; Bossuyt, Xavier; Musset, Lucille; Cervera, Ricard; Plaza-Lopez, Aresio; Dias, Carlos; José Sousa, Maria; Radice, Antonella; Eriksson, Catharina; Hultgren, Olof; Viander, Markku; Khamashta, Munther; Regenass, Stephan; Coelho Andrade, Luis Eduardo; Wiik, Allan; Tincani, Angela; Rönnelid, Johan; Bloch, Donald B.; Fritzler, Marvin J.; Chan, Edward K L; Garcia-De La Torre, I.; Konstantinov, Konstantin N.; Lahita, Robert; Wilson, Merlin; Vainio, Olli; Fabien, Nicole; Sinico, Renato Alberto; Meroni, Pierluigi; Shoenfeld, Yehuda.
In: Annals of the Rheumatic Diseases, Vol. 73, No. 1, 01.2014, p. 17-23.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies
AU - Agmon-Levin, Nancy
AU - Damoiseaux, Jan
AU - Kallenberg, Cees
AU - Sack, Ulrich
AU - Witte, Torsten
AU - Herold, Manfred
AU - Bossuyt, Xavier
AU - Musset, Lucille
AU - Cervera, Ricard
AU - Plaza-Lopez, Aresio
AU - Dias, Carlos
AU - José Sousa, Maria
AU - Radice, Antonella
AU - Eriksson, Catharina
AU - Hultgren, Olof
AU - Viander, Markku
AU - Khamashta, Munther
AU - Regenass, Stephan
AU - Coelho Andrade, Luis Eduardo
AU - Wiik, Allan
AU - Tincani, Angela
AU - Rönnelid, Johan
AU - Bloch, Donald B.
AU - Fritzler, Marvin J.
AU - Chan, Edward K L
AU - Garcia-De La Torre, I.
AU - Konstantinov, Konstantin N.
AU - Lahita, Robert
AU - Wilson, Merlin
AU - Vainio, Olli
AU - Fabien, Nicole
AU - Sinico, Renato Alberto
AU - Meroni, Pierluigi
AU - Shoenfeld, Yehuda
PY - 2014/1
Y1 - 2014/1
N2 - Anti-nuclear antibodies (ANA) are fundamental for the diagnosis of autoimmune diseases, and have been determined by indirect immunofluorescence assay (IIFA) for decades. As the demand for ANA testing increased, alternative techniques were developed challenging the classic IIFA. These alternative platforms differ in their antigen profiles, sensitivity and specificity, raising uncertainties regarding standardisation and interpretation of incongruent results. Therefore, an international group of experts has created recommendations for ANA testing by different methods. Two groups of experts participated in this initiative. The European autoimmunity standardization initiative representing 15 European countries and the International Union of Immunologic Societies/World Health Organization/Arthritis Foundation/Centers for Disease Control and Prevention autoantibody standardising committee. A three-step process followed by a Delphi exercise with closed voting was applied. Twenty-five recommendations for determining ANA (1-13), anti-double stranded DNA antibodies (14-18), specific antibodies (19-23) and validation of methods (24-25) were created. Significant differences between experts were observed regarding recommendations 24-25 ( p
AB - Anti-nuclear antibodies (ANA) are fundamental for the diagnosis of autoimmune diseases, and have been determined by indirect immunofluorescence assay (IIFA) for decades. As the demand for ANA testing increased, alternative techniques were developed challenging the classic IIFA. These alternative platforms differ in their antigen profiles, sensitivity and specificity, raising uncertainties regarding standardisation and interpretation of incongruent results. Therefore, an international group of experts has created recommendations for ANA testing by different methods. Two groups of experts participated in this initiative. The European autoimmunity standardization initiative representing 15 European countries and the International Union of Immunologic Societies/World Health Organization/Arthritis Foundation/Centers for Disease Control and Prevention autoantibody standardising committee. A three-step process followed by a Delphi exercise with closed voting was applied. Twenty-five recommendations for determining ANA (1-13), anti-double stranded DNA antibodies (14-18), specific antibodies (19-23) and validation of methods (24-25) were created. Significant differences between experts were observed regarding recommendations 24-25 ( p
UR - http://www.scopus.com/inward/record.url?scp=84889651539&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84889651539&partnerID=8YFLogxK
U2 - 10.1136/annrheumdis-2013-203863
DO - 10.1136/annrheumdis-2013-203863
M3 - Article
VL - 73
SP - 17
EP - 23
JO - Annals of the Rheumatic Diseases
JF - Annals of the Rheumatic Diseases
SN - 0003-4967
IS - 1
ER -